Sofinnova closes its second crossover fund at €725M, topping its €650M target, to back about 15 late-stage European biotechs ...
The FDA rejected a new cancer treatment from Summit Therapeutics and Akeso in a decision that analysts largely expected, but ...
For the third time in about two years, the FDA has cit­ed man­u­fac­tur­ing de­fi­cien­cies in re­ject­ing a drug com­bi­na­tion from Jiang­su Hen­grui Phar­ma­ceu­ti­cals and El­e­var Ther­a­peu­tics ...
Welcome back to another edition of Endpoints Weekly! The unseasonably warm autumn we’ve had in New York finally seems to be ...
Neurosterix raises $105M Series B for M4 PAM schizophrenia drug NTX-253, adding Karuna’s Andrew Miller as executive chair.
Rezera, a biotech developing drugs for cardio and inflammatory diseases, has delayed its IPO scheduled for Friday, a company ...
Endpoints’ Drew Armstrong and Max Bayer join policy expert Nick Shipley live Wednesday to break down what the US midterms ...
J&J’s trispecific ramantamig shows 100% ORR in newly diagnosed myeloma, Tibsovo hits EFS in frontline AML, Calquence combo ...
HHS announced ~$25M for psychedelics research, focusing on ibogaine via ARPA-H. Mark Cuban's Cost Plus Drugs and Beond will ...
Companies that committed to President Donald Trump’s drug pricing policy now face difficult decisions when launching new ...
Mirum’s hepatitis D drug brelovitug hits its Phase 3 goal in AZURE-4, setting up a 2027 filing against Gilead’s Hepcludex and ...
Oyster Therapeutics raises $60M Series A-2, with Lilly joining, for self-assembling oral degraders that target toxic tau in ...